How can rare disease market access benefit from cross-border and multi-stakeholder initiatives?
Rare diseases are often neglected by the traditional market access models, which focus on large patient populations and cost-effectiveness. However, rare disease patients deserve the same access to innovative and life-changing therapies as any other group. How can rare disease market access benefit from cross-border and multi-stakeholder initiatives? Here are some key aspects to consider.